UPCOMING SESSIONS in ET
Thu, Nov 5, 2026
6:00 – 7:00 AM Bangkok
Cardiac Manifestations, Medical Management and Amyloid Treatments Ayan Patel Register
UPCOMING SESSIONS in ET
Thu, Nov 5, 2026 · 6:00 – 7:00 AM Bangkok
Cardiac Manifestations, Medical Management and Amyloid Treatments
Ayan Patel
Register
View all sessions

Business

Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus
Jan 12, 2026
Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus
Not intended for UK MediaBayer bolsters development portfolio by acquisition of two investigational imaging agents (AT-01 and AT-05) from Attralus, Inc. to advance…
Read more
Long-term outcome of acquired transthyretin amyloidosis
Jan 06, 2026
Long-term outcome of acquired transthyretin amyloidosis
AbstractBackgroundAcquired transthyretin (ATTR) amyloidosis is increasingly reported among domino liver transplantation (DLT) recipients who receive livers from…
Read more
AL Amyloidosis vs ATTR-CM: Clinical Insights and Diagnostic Challenges
Jan 05, 2026
AL Amyloidosis vs ATTR-CM: Clinical Insights and Diagnostic Challenges
Accurate differentiation between light-chain (AL) amyloidosis and transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is critical for effective patient…
Read more
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Dec 31, 2025
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee –– In four out of five pending patients,…
Read more
Subscribe to